Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Changchun Qijian Biological Products is a specialized Chinese biopharmaceutical company focused on the research, development, and large-scale manufacturing of viral vaccines. As a key subsidiary of the China National Biotec Group (CNBG) under the Sinopharm umbrella, the company is a leading provider of live attenuated vaccines for varicella and mumps. Its production facilities are GMP-certified and designed to meet both domestic and international quality standards. The company plays a vital role in public health by supplying essential pediatric vaccines for national immunization programs. Changchun Qijian continues to expand its reach through product exports and ongoing improvements in vaccine stability and safety.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Changchun Qijian Biological Products.